Home/ Stocks/ VRCA

Verrica Pharmaceuticals Inc. Common Stock

VRCA XNAS

$5.08 -0.28 (-5.22%) ▼ 15-min delayed

Open

$5.31

High

$5.50

Low

$4.70

Volume

126.3K

Market Cap

$92.08M

About Verrica Pharmaceuticals Inc. Common Stock

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 76 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$5.02M	$-9,682,000	$-0.45
FY 2025	$35.58M	$-17,886,000	$-1.68
Q3 2025	$14.34M	$-274,000	$-0.03
Q2 2025	$12.70M	$204.0K	$0.02

Related Market News

No specific coverage for VRCA yet. Check out our latest market news or earnings calendar.

Get VRCA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Verrica Pharmaceuticals Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.